FAST STATS COVID-19 DEMOGRAPHICS 6.0%
is the current percentage decrease of 7-day average of daily new cases to 13,997 cases
94.4%
is the decrease in number of daily cases from a January 2021, 7-day average of 251,834 cases to June 15, 2021
number of US cases as of June 15,221
33,246,578 600,047 5
COVID-19 deaths in the US
is the number of variants of concern (VOC) that the CDC is now tracking
of the variant cases are B.1.1.7, the UK variant, is expected to increase 8 to 11%.
69% 90%
of the cases in the UK are B.1.617.2, and are from variant of interest Delta. The Delta variant, fi rst detected in India, accounts for more than 10% of all infections in the U.S, and may be responsible for more than 18% of cases in Western U.S. states.
is the number of vaccine doses that have been administered in the US from Dec. 14, 2020 to June 10, 2021
305.7 MILLION 86.5%
of people ages 65 or older have received at least one dose of vaccine and 75.8% are fully vaccinated.
64%
of people ages 18 or older have received at least one dose of vaccine and 53.4% are fully vaccinated.
Source: As of June 16, 2021 - Centers for Disease Control (CDC)
https://www.cdc.gov/coronavirus/2019-ncov/covid-data/ covidview/
index.html
Photo credit: sdecoret |
stock.adobe.com 6 July 2021 • HEALTHCARE PURCHASING NEWS •
hpnonline.com
NEWSWIRE
COVID-19 infections in U.S. emerged as early as December 2019, NIH study fi nds
A new antibody testing study examining samples originally collected through the National Institutes of Health’s All of Us Research Program found evidence of -o- infections in fi ve states earlier than had initially been reported, announced the agency. These findings were published in the journal Clinical Infectious Diseases. The results expand on fi ndings from a enters for Disease Control and Prevention (CDC) study that suggested SARS-CoV-2, the virus that causes COVID-19, was present in the US as far back as December 2019. In the All of Us study, researchers analyzed more than 24,000 stored blood samples contributed by program participants across all 50 states between Jan. 2 and March 18, 2020. Researchers detected antibodies against SARS-CoV-2 using two different serology tests in nine participants’ samples. These participants were from outside the major urban hotspots of Seattle and New York City, believed to be key points of entry of the virus in the US. The positive samples came as early as January 7 from participants in Illinois, Massachusetts, Mississippi, Pennsylvania and Wisconsin. Most positive samples were collected prior to the fi rst reported cases in those states, demonstrating the importance of expanding testing as quickly as possible in an epidemic setting. All of Us worked with Quest Diagnostics to test samples on the Abbott Architect SARS-CoV-2 IgG ELISA and the EUROIM- MUN SARS-CoV-2 ELISA (IgG) platforms. For a sample to be considered “positive” by the research team, it had to have positive results on both platforms, which target antibodies that bind to different parts of the virus. Both tests have emergency use authorization from the U.S. Food and Drug Administration (FDA).
In the All of Us study, researchers
looked in participant samples for a type of antibodies called IgG. These antibodies do not appear until about two weeks after a person has been infected, indicating that participants with these antibodies were exposed to the virus at least several weeks before their sample was taken. In this study, the fi rst positive samples came from participants in Illinois and Massachusetts on Jan. 7 and 8, 2020, respectively, suggesting that the virus was present in those states in late December.
All of Us expects to release more informa-
tion following further analysis and will offer participants whose samples were included in the study an opportunity to receive their
individual results. The presence of antibod- ies in one’s blood sample does not guarantee that a person is protected from the infection (has immunity), or that any such protection will last.
AHRMM21 conference moves to Nashville, new dates
The Association for Health Care Resource & Materials Management (AHRMM) has announced they have moved their annual event due to capacity restrictions recently placed a few weeks ago. The AHRMM21 Conference & Exhibition is now relocated to Nashville, TN, August 23 to 25. AHRMM’s top priority is providing their annual conference and exhibition attendees, speakers, sponsors and exhibitors with critical healthcare supply chain resources and education while following safety guidelines.
Moving the conference to Nashville will allow AHRMM to offer the same education and networking attendees have come to expect from AHRMM. AHRMM appreci- ates your understanding and the ability to reunite the healthcare supply chain com- munity in-person for the fi rst time in two years in Nashville.
Healthcare Purchasing News will be there to cover and participate in AHRMM21 and to recognize the HPN 2021 Supply Chain Department of the Year in Nashville. For more conference information, and to register for the conference, please visit the conference website. Please contact ahrmm@
aha.org if you have questions. https://
web.cvent.com/event/338c4f98-df62-470e- bbfa-97047705e1d2/summary
Premier Inc. names 2021 Breakthroughs Awards winners Premier Inc. announced the recipients of its Breakthroughs Awards recognizing industry leaders who are making a difference in healthcare. Richard A. Norling Premier Alliance Excellence Award Winner: Atrium Health This member exhibits deep strategic alignment with our alliance’s mission to transform healthcare together; consistently delivers an exceptional level of care, improving the health of its communities; supports Premier’s collaboration goals by freely sharing best practices and successes; and reduces costs and improves clinical quality and safety through broad utilization of Premier data, services and technology. Monroe E. Trout Premier Cares Award
Winner: Community Enhancement Col- laboration, Inc.
The annual Monroe E. Trout Premier
ares ward honors not-for-profi t com- munity agencies, programs and health
Page 8
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62
